Biomarker and Phenotypic Risk Factors for Breast Cancer Lymphedema

乳腺癌淋巴水肿的生物标志物和表型危险因素

• 批准号: 8884997
• 负责人: CHRISTINE A. MIASKOWSKI
• 金额: $ 96.78万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8884997
• 关键词: Affect; Applications Grants; Biological Markers; Breast Cancer Patient; Breast Cancer Risk Factor; Breast Cancer Treatment; Breast Cancer survivor; Candidate Disease Gene; Cellulitis; Characteristics; Clinical; Clinical Trials; Cyclophosphamide; DNA Methylation; Development; Diagnosis; Epigenetic Process; Foundations; Funding; Gene Expression; Genes; High Risk Woman; Individual; Intervention; Intervention Studies; Lead; Life; Liquid substance; Lymph; Lymphatic System; Lymphedema; Malignant Neoplasms; Measures; Molecular; Moods; Operative Surgical Procedures; Outcome; Pathway interactions; Patients; Phenotype; Physiological Processes; Prevalence; Prospective Studies; Proteins; Publishing; Quality of life; Radiation therapy; Recruitment Activity; Risk; Risk Factors; Sampling; Severities; Stratification; Subgroup; Symptoms; Testing; Time; United States; United States National Institutes of Health; Variant; Woman; Work; arm; base; cancer surgery; chemotherapy; cohort; disability; experience; functional disability; functional status; genetic predictors; high risk; interstitial; malignant breast neoplasm; novel strategies; prevent; public health relevance

 DESCRIPTION (provided by applicant): Lymphedema (LE) following treatment for breast cancer is the most common form of secondary LE in the industrialized world. It occurs in 20% to 87% of patients following treatment for breast cancer and results in significant disability. At the present time, the definitive phenotypic, genotypic and epigenotypic predictors that place patients at highest risk for the development of LE are not known. Therefore, the specific aims of this study, in a sample of patients following treatment for breast cancer, are to: determine genetic predictors of LE using a candidate gene approach and evaluate for epigenetic changes, as measured by DNA methylation and subsequent gene expression, in candidate genes associated with the diagnosis of LE. The secondary aims of this study are to: evaluate for latent classes of women with distinct phenotypic predictors of LE; and evaluate for differences in symptoms, functional status, and QOL outcomes between women with and without LE and among the latent classes with LE. The results of this study will provide new information on the underlying mechanisms for LE and allow for the development and testing of novel approaches to prevent or reduce the negative effects of LE.

 描述（由申请人提供）：乳腺癌治疗后的淋巴水肿（LE）是工业化世界中最常见的继发性LE形式。它发生在20%至87%的乳腺癌治疗后的患者中，并导致严重残疾。在 目前，确定性的表型、基因型和表观基因型预测因子尚不清楚，这些预测因子使患者处于发生LE的最高风险中。因此，在乳腺癌治疗后的患者样本中，本研究的具体目的是：使用候选基因方法确定LE的遗传预测因子，并评估与LE诊断相关的候选基因中的表观遗传变化，如通过DNA甲基化和随后的基因表达所测量的。本研究的次要目的是：评估具有不同LE表型预测因子的潜在女性类别;并评估患有LE和未患有LE的女性之间以及患有LE的潜在类别之间在症状、功能状态和QOL结局方面的差异。这项研究的结果将为LE的潜在机制提供新的信息，并允许开发和测试新的方法来预防或减少LE的负面影响。